류마티스관절염 환자에서 종양궤사인자 차단제 사용 후에 발생한 폐렴 2 예

• 영문명: Two cases of Pneumonia after use of Tumor Necrosis Factor-alpha Antagonist in patients with Rheumatoid arthritis
• 발행기관: 조선대학교 의학연구원
• 저자명: 원희관(Hee-Kwan Won) 이재광(Jae-Kwang Lee) 허지안(Ji-An Hur) 조호찬(Ho-Chan Cho) 김현숙(Hyun-Sook Kim)
• 간행물 정보: 『The Medical Journal of Chosun University』제33권 제3호, 75~80쪽, 전체 6쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2008.09.30

영문 초록

Rheumatoid arthritis (RA) is provoked by autoimmune process. Chronic inflammation of synovial membrane induces cartilagenous destruction and bony erosion which finally lead to severe joint dam age and functional disability. For the treatment of RA, there are classic materials such as steroid, methotrexate. And recently, biological agents have been developed and among them tum or necrosis antagonists is most often used. These tum or necrosis factoralpha (TN F-a) antagonists are welcomed to its more noticeable effect in treatment of RA rather than disease modifying anti-rheumatic drug (DM A RD). In spite of its dramatic effect against RA, it is now reported that the use of TN F-a antagonist increases the risk of infection such as bacterial pneumonia and tuberculosis. We report here two cases of newly-developed pneumonia in patients with RA after use of TN F-a antagonist, etanercept.

목차

서 론

증 례 1

증 례 2

고 찰

요 약

키워드

Tumor necrosis factor-a antagonist Rheumatoid arthritis Pneumonia